DON’T FORGET!.To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected!.Linkedin: Instagram: Bluesky:

RT @BeatMoeckli: 🎉 Congrats to @Transpl_Int for an outstanding session at #ESOTcongress—highlighting top research!. 👏 Kudos to @DrSamratRay….

Be careful!!.

RT @Transpl_Int: STAY TUNED!!. To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other pl….

REMEMBER!!!.To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected!.Linkedin: Instagram: Bluesky:

STAY TUNED!!. To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected!.Linkedin: Instagram: Bluesky:

WHAT’S NEW?.To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected!.Linkedin: Instagram: Bluesky:

RT @ninapilat: Check out the @Transpl_Int February issue 🤩.

REMEMBER!.To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected!.Linkedin: Instagram: Bluesky:

DID YOU DO IT?.To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected!.Linkedin: Instagram: Bluesky:

DON’T FORGET!.To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected!.Linkedin: Instagram: Bluesky:

DON’T FORGET!.To ensure we share cutting-edge research & key discussions where they matter most, we will focus on other platforms & post less frequently here. Stay connected!.Linkedin: Instagram: Bluesky:

📖 Read the full publication & see the visual abstract:.Frontiers Publishing Partnerships | Desensitization With Imlifidase for HLA-Incompatible Deceased Donor Kidney Transplantation: A Delphi International Expert Consensus .Register here: (6/6)

📅 Mark your calendar!.🗓 March 17, 2025 – 17:00 CET.📍 Live Zoom Session (45 min).👥 Open to all, esp. young transplant professionals!.Don’t miss this chance to engage with top experts on a cutting-edge topic! .Register here: (5/6).

🎤 Expert Panelists:.🔹 Ondrej Viklicky, Director of the Transplantation Centre, Prague – leading nephrologist & transplant scientist. 🔹 Oriol Bestard, Chief of Nephrology, Vall d’Hebron, Barcelona – expert in immune-monitoring & translational research. (4/6).

👩‍⚕️ Who’s presenting?.🔹 Lucrezia Furian, Assoc Prof of Surgery, Univ of Padua, Past Chair @ESOT EKITA.🔹 Expert in transplant immunology & novel immunosuppression strategies.She’ll break down the key findings & clinical relevance of this consensus! .(3/6).

🚨 Why is this important?.Highly sensitized patients face longer wait times, fewer organ offers, & higher rejection risk. Imlifidase, a rapid IgG-cleaving enzyme, may change this—but clinical guidance is needed!.This expert consensus aims to bridge that gap. (2/6)

📢 Join our next @Transplant International Journal Club!.We’ll dive into a Delphi consensus on imlifidase for HLA-incompatible kidney transplantation in highly sensitized patients. 🏥💉 #Transplantation #KidneyTransplant (1/6).Register here:

To ensure we share cutting-edge research and key discussions where they matter most, we will focus on other platforms and post less frequently here. Stay connected with us:.Linkedin: Instagram: Bluesky:

“Evaluating Risk in Kidney Living Donors”. Read more here: #risk #living #donor #kidney #transplant .@ESOTtransplant @Lucreziafurian @AnkaraUni